Results 71 to 80 of about 16,591 (206)

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background Prostate cancer (PCa) is the most common malignant tumor in men, but the widely used prostate‐specific antigen (PSA) test has limited diagnostic accuracy. Research proposes that the loss of the Y chromosome (LOY) may affect the occurrence and development of prostate cancer, aiming to assess its potential as a diagnostic biomarker to
Jun Lu, Yan Lu, Takuro Kobayashi, Tsuyoshi Hachiya, Haruhiko Wakita, Yiming Jin, Yasunari Tanaka, Yoshihiro Ikehata, Masayoshi Nagata, Hisamitsu Ide, Shigeo Horie   +10 more
wiley   +1 more source

Treatment Response and Outcomes of Prostate Cancer Patients Carrying the Germline MMS22L F722fs Mutation

The Prostate, EarlyView.
ABSTRACT Background Methyl Methanesulfonate‐Sensitivity Protein 22‐Like (MMS22L) plays a key role in homology‐directed DNA repair, and experimental models have shown that its loss confers sensitivity to Poly (ADP‐ribose) polymerase inhibitors (PARPi).
Mayuko Kanayama, Violet A. Daniels, Marta Gielzak, Alex Brame, Misop Han, Li Jia, Jianfeng Xu, Tamara L. Lotan, Mario A. Eisenberger, Catherine H. Marshall, Patrick C. Walsh, William B. Isaacs, Jun Luo   +12 more
wiley   +1 more source

A Review Study on prostate cancer. Incidence, diagnosis and biomarkers: epithelial cadherin and related molecules [PDF]

, 2017
El cáncer de próstata (CaP) es un tumor maligno originado en las células prostáticas, siendo el subtipo más frecuente denominado adenocarcinoma. A nivel mundial, el CaP es el cuarto cáncer más común combinando ambos sexos y el segundo más común en ...
Besso, María José, Mencucci, Maria Victoria, Rosso, Marina, Vazquez, Monica Hebe   +3 more
core  

Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy [PDF]

, 2020
PURPOSE: To determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC. PATIENTS AND METHODS: In a Local CRPC cohort, 42 prostatic specimens were collected from patients who were ...
Deng, Tuo, Ge, Rongbin, Lin, Xueming, Long, Xingbo, Olumi, Aria F., Taplin, Mary-Ellen, Wang, Hongbo, Wang, Zongwei, Wu, Chin-Lee, Wu, Shulin, Zhang, Zhenwei   +10 more
core   +2 more sources

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis

The Prostate, EarlyView.
ABSTRACT Background In prostate cancer (PCa), smoking history is associated with more aggressive clinicopathological features, reduced efficacy of androgen deprivation therapy, and poorer overall survival (OS). However, its impact on survival outcomes in patients receiving taxane chemotherapy, poly ADP‐ribose polymerase inhibitor (PARPi), or immune ...
Tomoya Hatayama, Yohei Sekino, Go Kobayashi, Kazuma Yukihiro, Yoshinori Nakano, Shinsaku Tasaka, Naofumi Nomura, Yuki Kohada, Kenshiro Takemoto, Miki Naito, Shunsuke Miyamoto, Kohei Kobatake, Hiroyuki Kitano, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Nobuyuki Hinata   +16 more
wiley   +1 more source

[18F] PSMA PET‐CT and [18F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests

The Prostate, EarlyView.
ABSTRACT Background To compare choline PET‐CT and PSMA PET‐CT in a cohort of patients with high‐risk localized prostate cancer, assessing the diagnostic capacity of both tests. whose therapeutic approach could be modified based on the results. Methods An observational study was conducted in 116 patients with high‐risk prostate cancer between January ...
M. A. Tárraga‐Honrubia, A. S. Salinas‐Sánchez, S. Navarro‐Jiménez, M. V. Lorenzo‐Sánchez, P. Carrión‐López, J. M. Giménez‐Bachs   +5 more
wiley   +1 more source

Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer [PDF]

, 2014
Metastatic prostate cancer (PCa) is still an incurable disease. Long non-coding RNAs (lncRNAs) may be an overlooked source of cancer biomarkers and therapeutic targets.
Castori-Eppenberger, Serenella, Chi, Kim N., Crea, Francesco, Farrar, William L., Helgason, Cheryl D., Isogai, Takao, Lam, Wan L., Lin, Dong, Morant, Rudolf, Parolia, Abhijit, Pikor, Larissa, Quagliata, Luca, Wang, Yuwei, Wang, Yuzhuo, Watahiki, Akira, Xue, Hui   +15 more
core   +1 more source

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy

The Prostate, EarlyView.
ABSTRACT Background Radiographic progression (RP) without prostate‐specific antigen (PSA) elevation has emerged as a clinically important pattern in the androgen receptor pathway inhibitors (ARPI) era, but its prevalence and prognostic significance in real‐world metastatic hormone‐sensitive prostate cancer (mHSPC) cohorts remain unclear.
Takeshi Tsutsumi, Shogo Yamazaki, Takuya Matsuda, Takuya Tsujino, Taizo Uchimoto, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Fumihiko Urabe, Masanobu Saruta, Atsuhiko Yoshizawa, Shingo Toyoda, Saizo Fujimoto, Kyosuke Nishio, Moritoshi Sakamoto, Tatsuo Fukushima, Ko Nakamura, Kazuki Nishimura, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Ryoichi Maenosono, Kiyoshi Takahara, Teruo Inamoto, Takahiro Kimura, Kazutoshi Fujita, Kazumasa Komura, Haruhito Azuma   +27 more
wiley   +1 more source

Câncer de próstata resistente à castração: estado atual do tratamento com Rádio-223 associado com anti-androgênios ( enzalutamida e abiraterona ) - uma revisão sistemática da literatura [PDF]

, 2016
INTRODUÇÃO. Recentemente, uma nova gama de opções terapêuticas tornou-se disponível para homens com câncer de próstata resistente à castração (CPRC), incluindo anti-androgênios (acetato de abiraterona, enzalutamida), taxanos (docetaxel, cabazitaxel) e um
Added Filho, Daniel Abdalla, Benedetto Filho, Marcos Sidney, Sapienza, Marcelo Tatit   +2 more
core   +2 more sources

Tributyltin Protumorigenic Effects Targeting Prostate Cancer Cell Metabolism, Proliferation, Migration, and Invasion

Environmental Toxicology, EarlyView.
ABSTRACT Prostate cancer (PCa) is an endocrine‐related cancer highly dependent on androgenic signaling. Beyond hormone dependence, extrinsic factors play a significant role in the risk of developing PCa, which raises concern about the influence of environmental compounds such as endocrine‐disrupting chemicals (EDCs). Tributyltin (TBT) is an EDC used in
Mariana Feijó, Luís P. Brás, Catarina M. D. Serra, Lara R. S. Fonseca, Sara Correia, Bruno J. Pereira, Ana P. Duarte, Henrique J. Cardoso, Cátia V. Vaz, Sílvia Socorro   +9 more
wiley   +1 more source